[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:
3-Oct-2013

[ | E-mail ] Share Share

Contact: Robert Sanders
rlsanders@berkeley.edu
510-643-6998
University of California - Berkeley
@UCBerkeleyNews

Blocking nerve cells could prevent symptoms of eczema

New picture of interaction between nervous & immune systems could lead to novel therapies

IMAGE: The itch and inflammation of eczema may be prevented by itch-receptor blockers, based on new research linking the nervous system and the immune system.

Click here for more information.

A new picture of how the nervous system interacts with the immune system to cause the itch and inflammation associated with eczema, a chronic skin disease, could lead to new therapies for the condition, according to University of California, Berkeley, scientists.

Some 10 percent of the population suffers from eczema, or atopic dermatitis, at some point in their lives, but there are no cures or even good treatments for it. Symptoms range from dry, flaky and itchy skin to flaming red rashes, and in severe cases, particularly in children, the disease often progresses to nasal allergies and asthma.

Eczema's cause is unknown, but most research today focuses on the immune system's role in reacting to chemicals that cause itching and inflammation. UC Berkeley neuroscientist Diana M. Bautista and graduate students Sarah R. Wilson and Lydia Thé, however, discovered that sensory nerves in the skin are the first to react to these chemicals, and that blocking the skin's itch receptors not only stops the scratching, but may head off the worst consequences of eczema.

"Most drug development has focused on trying to find a way to inhibit the immune response," said Bautista, assistant professor of molecular and cell biology and a member of the Helen Wills Neuroscience Institute. "Now that we have found that sensory neurons may be the first responders, that changes how we think about the disease."

"By just blocking what is happening in the neurons, you could block the symptoms of chronic itch, including the big immune response leading to asthma and allergy," Wilson added. "And you prevent the patient from scratching, which damages skin cells and makes them release more chemicals that cause inflammation and help maintain chronic itch."

The researchers already have identified a potential drug, now in Phase 1 clinical trials for a different inflammatory disease, that stops mice from scratching when it is applied to the skin.

Their new model of eczema is based on findings reported online today (Thursday, Oct. 3) in the journal Cell by Bautista, Wilson, Thé and their UC Berkeley colleagues.

Block that wasabi

"We started out looking at acute itch and asked the question, 'Why do we scratch? Why do we have that urge, and how does it work that scratching gives you some relief, when normally it feels terrible if you don't have an itch and scratch yourself that hard?'" Bautista said. "But the many types of chronic itch that humans experience are all very different. We believe that, through identifying molecular mechanisms, we can find new treatments and therapies for these diseases."

Immunologists several years ago identified a chemical - TSLP (thymic stromal lymphopoietin), a so-called cytokine - that induces itch when expressed in the skin. Because immune cells have receptors for this chemical, TSLP triggers them to release chemicals that attract other immune cells and to create the red, itchy inflammation typical of eczema. These inflammatory chemicals seem to spread through the body and induce inflammation in the lungs, gut and nasal passages that lead to asthma and allergies, Bautista said.

Wilson and Bautista, however, focused on what causes the immediate or acute itch. Probing itch-sensitive neurons in the skin, they found that these neurons also have receptors for TSLP, and that TSLP makes these neurons, like immune cells, release chemical mediators that cause inflammation. Furthermore, by looking at human skin cells (keratinocytes) in culture, they discovered the triggers that make skin cells release TSLP in the first place.

"Our hypothesis is that skin cells release TSLP, which triggers neurons to release mediators that lead to more inflammation and recruitment of immune cells," helping to set up chronic inflammation, Bautista said.

"These itch-sensitive neurons are a small population," she added. "If we could just block the 2 percent of neurons that respond to TSLP, we could have a really selective drug that treats chronic itch, but keeps all of the important functions of skin - normal pain function, normal temperature and tactile sensations - and the many parts of the immune system intact."

Interestingly, the TSLP receptor works through an ion channel, TRPA1, that Bautista discovered when she was a post-doctoral researcher. The channel was named the wasabi ion channel because it is sensitive to "mustard compounds" like those found in Dijon or wasabi. Blockers of the wasabi channel thus would block the action of TSLP and stop itch.

Alternatively, Wilson said, drug developers could look for chemicals that block the release of TSLP from damaged skin cells.

Bautista and her colleagues are continuing to explore the relative contributions of different types of nerve and immune cells to atopic dermatitis and chronic itch and are developing mouse models in which to test their hypotheses.

###

The research was funded by grants from the National Institutes of Health (AR059385 & DOD007123A). Other paper co-authors are Lyn M. Batia, Katherine Beattie, George E. Katibah, Shannan P. McClain, Maurizio Pellegrino and Daniel M. Estandian of UC Berkeley's Department of Molecular and Cell Biology.



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.